Mark Talamonti to Severity of Illness Index
This is a "connection" page, showing publications Mark Talamonti has written about Severity of Illness Index.
Connection Strength
0.661
-
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020 01; 20(1):95-104.
Score: 0.119
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.108
-
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther. 2016 06; 20(3):227-30.
Score: 0.094
-
Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy. J Surg Oncol. 2014 Sep; 110(4):400-6.
Score: 0.082
-
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study. Arch Dermatol Res. 2022 Aug; 314(6):593-603.
Score: 0.066
-
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology. 2011; 222(3):250-5.
Score: 0.066
-
National failure to operate on early stage pancreatic cancer. Ann Surg. 2007 Aug; 246(2):173-80.
Score: 0.051
-
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):958-964.
Score: 0.032
-
Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery. 2017 11; 162(5):1032-1039.
Score: 0.026
-
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin Dev Immunol. 2012; 2012:823854.
Score: 0.018